Two ADAURA analyses support use of Osimertinib for patients with surgically resected, Stage IB to IIIA non-small cell lung cancer
(Singapore–16:45 p.m. SPT/3:45 EST January 29, 2021)–Two presentations from the ADAURA clinical trial advanced previous research that demonstrated improved disease-fee survival (DFS) outcomes for patients with surgically resected non-small cell lung cancer (NSCLC) receiving osimertinib. The data were reported today at the International Association for the Study of Lung Cancer’s 2020 World Conference on Lung…
Details